Minorities Seek Presence On Cancer Review Panels

The mortality rate for prostate cancer is twice as high for African American men as it is for white men. The mortality rate for breast cancer is 1.35 times higher for African American women than for white women. Because of these discrepancies, reported by the National Center for Health Statistics, review panels that make cancer research funding decisions should include more African Americans, contend minority cancer advocates. "Without representation, there's not going to be funding," says W.

Written byPaul Smaglik
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

The mortality rate for prostate cancer is twice as high for African American men as it is for white men. The mortality rate for breast cancer is 1.35 times higher for African American women than for white women. Because of these discrepancies, reported by the National Center for Health Statistics, review panels that make cancer research funding decisions should include more African Americans, contend minority cancer advocates.

"Without representation, there's not going to be funding," says W. Bedford Waters, chairman of the urology section of the National Medical Association, a Washington, D.C.-based professional organization for African American physicians. And without funding, science lacks the firepower to ask questions about the cause of the discrepancies, maintains Waters, a professor and associate director of urology at Loyola University Medical Center in Chicago. "Is it genetic? is it environmental? Is it dietary?" he asks.

Those unanswered questions prompted the American Cancer Society's (ACS's) ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies